Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Opdualag off to a flying start, says BMS CEO
Opdualag off to a flying start, says BMS CEO
Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a “great start”, according to chief executive ...
Dupixent drives Sanofi to hike its full-year profit forecasts
Dupixent drives Sanofi to hike its full-year profit forecasts
Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year earnings forecasts. ...
Biogen gets much-needed pipeline lift with speedy ALS drug review
Biogen gets much-needed pipeline lift with speedy ALS drug review
Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months. ...
Gingko Bioworks to Acquire Zymergen in Deal Worth $300 Million
Gingko Bioworks to Acquire Zymergen in Deal Worth $300 Million

Massachusetts-based Gingko Bioworks is aiming to expanding its pipeline of potential drug candidates with the purchase of Zymergen. 

Pfizer and BioNTech Push Hard on Omicron-Specific Vaccine While Fending Off Lawsuits
Pfizer and BioNTech Push Hard on Omicron-Specific Vaccine While Fending Off Lawsuits
While there’s no doubt about the success of the Pfizer and BioNTech COVID-19 vaccines, with that kind of success comes significant scrutiny and legal action.  ...
Teva Proposes $5B Settlement for Thousands of Opioid Lawsuits
Teva Proposes $5B Settlement for Thousands of Opioid Lawsuits
In its second quarter financial report this year, Teva Pharmaceuticals announced that it had arrived at an almost $5-billion settlement for thousands of pending opioid liability lawsuits. ...
As Omicron Mutates, Researchers Compare Efficacy of Therapeutic Antibodies and Antivirals
As Omicron Mutates, Researchers Compare Efficacy of Therapeutic Antibodies and Antivirals
As the BA.4 and BA.5 Omicron subvariants become the dominant strains of COVID-19 around the world, researchers are evaluating just how well vaccines and therapies work against these extremely infec...
FDA’s Oncologic Drugs Advisory Committee to Discuss Three NDA Cancer Drugs
FDA’s Oncologic Drugs Advisory Committee to Discuss Three NDA Cancer Drugs

The FDA has scheduled a meeting of its Oncologic Drugs Advisory Committee on Sept. 22 and 23 to discuss New Drug Applications (NDA) for three cancer drugs.

Researchers discover gene that promotes muscle strength during exercise
Researchers discover gene that promotes muscle strength during exercise
Researchers have identified a gene that promotes muscle strength when switched on by physical activity, unlocking the potential for the development of therapeutic treatments to mimic some of the be...
Years of Alzheimer's research were based on a key finding. Now an investigation alleges it was faked, and the work may have been wasted.
Years of Alzheimer's research were based on a key finding. Now an investigation alleges it was faked, and the work may have been wasted.

Results of a seminal 2006 Alzheimer's paper appear fabricated, an investigation said. 

Pfizer to Spend $470 Million in Expansion of Vaccine Research Facilities
Pfizer to Spend $470 Million in Expansion of Vaccine Research Facilities
Pfizer is planning a $470 million expansion of its vaccine research facility in Pearl River, N.Y. which played a leading role on the co-development of the company’s COVID-19 vaccine with BioNTech...
Takeda’s Hyqvia Shows Promise for CIDP in Phase 3 Study
Takeda’s Hyqvia Shows Promise for CIDP in Phase 3 Study
Takeda’s investigational drug Hyqvia (immune globulin with recombinant human hyaluronidase) showed promise in a late-stage clinical trial for patients with chronic inflammatory demyelinating poly...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand